Novo Nordisk A/S (NVO)
Last Price$88.15.2%
Market Cap$392.3B
LTM EPS
DKK 22.7
-17.3% YOY growth
NTM EPS
DKK 26.3
+15.9% YOY growth
Current P/E
27.7x LTM
23.0x NTM
52w high P/E
51.2x LTM
44.0x NTM
52w low P/E
24.4x LTM
20.3x NTM
10Y avg P/E
28.4x LTM
10.6x NTM
NVO Peter Lynch Chart
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
Explore more intrinsic value tools hub for NVO
Earnings growth model
Peter Lynch Fair Value
Earnings Power Value
Discount rate
Ben Graham Fair Value
Reverse DCF
Relative Value
Intrinsic Value
DCF value calculator
Margin of safety
FAQ
What is Novo Nordisk A/S earnings per share (EPS)?
Novo Nordisk A/S earnings per share (EPS) for the twelve months ending Feb 21, 2025 was DKK 22.7, a (17.3%) increase year-over-year.
What is Novo Nordisk A/S Price to Earnings (P/E) ratio?
As of Feb 21, 2025, Novo Nordisk A/S's P/E ratio is 27.7x. This is calculated by dividing the current share price of $88.1 by the Earnings per Share (EPS) for the trailing twelve months, which is DKK 22.7. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.
Is Novo Nordisk A/S overvalued or undervalued?
Novo Nordisk A/S is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $60.9, compared to a market price of around $88.1. This suggests a potential overvaluation of 30.9%.